7 23 amoebae and human cells. Protection from human serum occurs after amoebae have undergone trogocytosis, 24 but not phagocytosis, suggesting protection is not generally associated with ingestion. Furthermore, mutant 25 amoebae that are deficient in performing phagocytosis but not trogocytosis are still protected from human 26 serum. Collectively, these findings support that amoebae acquire and display human cell membrane proteins 27 through trogocytosis and that this leads to protection from lysis by human serum complement. These studies 28 have major implications for interactions between E. histolytica and the immune system. Display of human cell 29 proteins acquired during trogocytosis is a novel strategy for immune evasion by a pathogen. Since other 30 microbial eukaryotes use trogocytosis for cell killing, this may apply to the pathogenesis of other infections. 78 survived exposure to human serum ( Fig 3E) . Therefore, trogocytosis is associated with subsequent protection 79 from lysis by human serum.
80 Protection from human serum lysis is dependent on contact with human cells 81 We next asked if protection from serum lysis required direct contact between amoebae and human 82 cells, in order to determine if protection is a consequence of trogocytosis, or if protection could be acquired 83 through secretion of proteins or release of exosomes by human cells. Amoebae and human cells were co-84 incubated in transwell dishes, with or without direct contact ( Fig 4A) . After incubation, cells from the lower 85 chambers were exposed to human serum and imaging flow cytometry was used to measure amoeba viability. 86 Human cells were not able to pass through transwell membranes ( Fig 4B) . Protection from complement lysis 87 occurred only when amoebae and human cells were incubated together in the same chamber of the transwell, 88 but not when they were separated ( Fig 4C) . Protection from human serum thus required direct contact 89 between amoebae and human cells, supporting a requirement for trogocytosis in the acquisition of 90 protection.
91 Protection from human serum requires actin 92 Since amoebic trogocytosis requires actin rearrangement [19] , and acquisition and display of human 93 cell membrane proteins requires actin (Fig 2) , we next asked if treatment with cytochalasin D would also 94 abrogate protection from human serum. Amoebae were treated with cytochalasin D, incubated in the 95 presence or absence of human cells, and then exposed to human serum. Imaging flow cytometry was used to 96 simultaneously measure trogocytosis ( Fig 5A) and amoeba viability ( Fig 5B) . Amoebae that were treated with 97 cytochalasin D were impaired in their ability to undergo trogocytosis and were not protected from serum lysis 98 after co-incubation with human cells. Actin rearrangements are thus required for subsequent protection from 99 lysis by human serum.
Protection occurs after trogocytosis and does not occur after phagocytosis

01
To ask if protection from human serum specifically occurs after trogocytosis, or if any form of ingestion 02 leads to protection from serum, we compared amoebae that had undergone trogocytosis versus those that 03 had undergone phagocytosis. We previously showed that amoebae undergo trogocytosis of live human cells, 04 and in contrast, undergo phagocytosis of pre-killed human cells [19] . Therefore, we asked if phagocytosis of 05 pre-killed cells could also provide protection from complement lysis. Human cells were pretreated with 06 staurosporine to induce apoptosis ( Fig 6A) . Amoebae were co-incubated with live or pre-killed human cells or 07 incubated in the absence of human cells. Amoebae that had undergone trogocytosis or phagocytosis ingested 08 a similar amount of human cell material ( Fig 6B) , however, amoebae were only protected from lysis by human 09 serum after undergoing trogocytosis ( Fig 6C) . Therefore, protection from lysis by human serum occurs 10 specifically after trogocytosis of live cells and not phagocytosis of pre-killed cells.
11
To further distinguish between requirements for trogocytosis and phagocytosis, we next tested 12 knockdown mutants deficient in rhomboid protease 1 (EhROM1) (EHI_197460), a rhomboid protease with 13 roles in attachment and ingestion [39, 40] . EhROM1 mutants have been shown to be deficient in both 14 phagocytosis and pinocytosis, as well as attachment to live cells [39, 40] . Furthermore, it has been shown that 15 silencing of EhROM1 does not change susceptibility to serum lysis, making these mutants an ideal tool for 16 testing the effects conferred by ingestion of human cells [39, 40] . We generated stable transfectants knocked 17 down for expression of EhROM1 ( Fig 7A) . EhROM1 knockdown mutants were deficient in attachment to 18 healthy human cells ( Fig 7B-C) , consistent with previous studies [40] . Also consistent with previous studies, 19 EhROM1 mutant amoebae incubated alone were not more susceptible to serum lysis then control amoebae 20 (S5B Fig) . Using imaging flow cytometry, we assayed EhROM1 mutants for a trogocytosis defect for the first 21 time and found that they did not exhibit a defect in trogocytosis of live human cells ( Fig 7D, S6 Fig) . Consistent 22 with previous studies [40], we found that EhROM1 mutants were defective in phagocytosis of pre-killed 23 human cells ( Fig 7E) . After co-incubation with live human cells, EhROM1 mutants were no more or less 24 protected from lysis by human serum than control amoebae ( Fig 7F, S5 Fig) . Therefore, a mutant deficient in 12 25 phagocytosis does not exhibit a difference in protection from serum, further supporting that phagocytosis is 26 not involved in resistance to lysis by human serum. Moreover, resistance to lysis by human serum is not 27 associated with simple attachment to human cells, since EhROM1 mutants are impaired in binding to live 28 human cells but still exhibit no difference in resistance to human serum. Together, these finding further 29 underscore that protection from lysis by human serum is associated with trogocytosis, not phagocytosis.
30
Collectively, these results support a new model of immune evasion in which amoebae perform 31 trogocytosis on live human cells and through trogocytosis, acquire and display human cell membrane proteins.
32 Display of human cell membrane proteins then leads to protection from human serum, most likely by 33 inhibiting complement-mediated lysis (Fig 8) . 
51
Previous studies have hinted that amoebae become more resistant to complement after interacting 52 with host cells or tissues, and that complement resistance involves proteins on the amoeba surface.
53 Consistent with our findings, it has previously been demonstrated that amoebae that were made resistant to 54 complement lysis by hamster liver passage, lost resistance after treatment with trypsin [38], suggesting that 55 complement-resistance is associated with proteins on the amoeba surface. It has also been shown that 56 amoebae acquire serum resistance after ingestion of live human erythrocytes, and that resistant amoebae 81 proteins are present in lipid microdomains (e.g., lipid rafts), or are in clusters. It is also possible that while 82 patchy foci of acquired membrane proteins are clearly seen, these proteins may also be found throughout the 83 membrane at lower concentrations below the limit of detection. In any case, the distribution of human cell 84 proteins appears sufficient to confer protection from complement.
85
With the discoveries of amoebic trogocytosis and display of human cell membrane proteins, a new 86 paradigm for amoeba-human cell interactions is emerging. We previously showed that when amoebae kill 87 cells, they do not ingest dead cell corpses [19] . Prior to this, amoebae were thought to fully ingest the corpses 88 of the cells they had killed [5, 55, 56] . Now, with the discovery of acquisition and display of human cell 89 membrane proteins, together with the lack of ingestion of cell corpses, a different paradigm is emerging. It is 90 possible that rather than acquiring nutrition by killing and ingesting entire cells, amoebae nibble and acquire 91 membrane proteins that contribute to immune evasion. Invasive disease involves survival of amoebae in blood 92 vessels. Since trogocytosis contributes to tissue invasion [19] , it is possible that amoebae acquire human cell 93 membrane proteins as they invade the intestine. Amoebae would then be equipped to survive in the 94 bloodstream and to spread to other tissues. Moreover, since there is the potential for a variety of human cell 95 proteins to be displayed, display of human cell proteins may impact host-amoeba interactions in many ways.
96
Display of human cell proteins acquired during trogocytosis is a novel strategy for immune evasion by a 97 pathogen. Since other microbial eukaryotes use trogocytosis for cell killing, including N. fowleri, there is the 98 potential for display of acquired membrane proteins to apply to the pathogenesis of other infections.
99 Furthermore, our studies extend acquisition and display of membrane proteins beyond mammalian immune 00 cells, suggesting that this may be a fundamental feature of eukaryotic trogocytosis. How membrane proteins 01 are acquired and displayed by immune cells during trogocytosis is not well understood in immune cells and, to 02 our knowledge, the underlying mechanism is not under investigation. Thus, ongoing studies in amoebae may 03 shed light on acquisition and display of membrane proteins during trogocytosis.
04
In summary, we have shown that amoebae display human cell membrane proteins on their surface and 12 Amoebae with 3 or more attached human cells were scored as attachment positive. Image collection and 13 scoring were performed in a blinded manner.
14 Imaging flow cytometry analysis 15 Samples were run on an Amnis ImageStreamX Mark II and 10,000 events were collected per sample. 16 Data were analyzed using Amnis IDEAS software. Samples were gated on focused cells, single amoebae, 17 amoebae that had come in contact with human cells, and amoebae that had internalized human material.
18 From the single amoebae gate, amoebic death was quantified by plotting intensity of LIVE/DEAD Violet against 19 side scatter and gating on LIVE/DEAD Violet positive cells (see Fig. S3 ).
20
In the biotin transfer experiment, single amoebae were divided into Hoechst high and Hoechst low 21 populations in order to isolate single amoebae with and without human cells. Overlap of biotin with CMFDA 22 labeled amoebae was plotted and biotin positive cells were selected from both Hoechst high and low 23 populations (see Fig. S1 ). In the trogocytosis and phagocytosis assays, focused cells were gated from total collected events. Next, 25 single cells were gated, and then single amoebae were gated. Amoebae positive for human cells were gated 26 and internalization of human cells was measured. (see Fig. S5 )
27 Statistical analysis 28 All statistical analysis was performed using GraphPad Prism. All data plots display means and standard 29 deviation values. Data were statistically analyzed using a student's unpaired t-test (ns = P>0.05, * = P ≤ 0.05, 30 ** = P ≤ 0.01, *** = P ≤ 0.001, **** = P ≤ 0.0001).
